Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Crofelemer source : Jaguarhealth.gcs-web.com save search
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
Published: 2023-08-30 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -2.28%
H: 0.5%
C: -4.94%
rare disease crofelemer
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Published: 2023-08-17 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -4.06%
H: 0.41%
C: -2.97%
diarrhea health cancer treatment family crofelemer trial
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Published: 2023-08-08 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
fda drug disease health microvillus treatment application crofelemer
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published: 2023-08-07 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 1.2%
H: 3.33%
C: 0.63%
diarrhea breast cancer crofelemer study
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Published: 2023-08-01 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 1.02%
H: 0.67%
C: -2.84%
fda drug diarrhea health treatment application crofelemer
Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Published: 2023-05-25 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -3.95%
H: 5.14%
C: -5.07%
diarrhea cancer crofelemer trial
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Published: 2023-05-09 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -0.68%
H: 0.54%
C: -6.28%
diarrhea cancer crofelemer trial
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
Published: 2023-02-28 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -0.51%
H: 1.52%
C: -2.54%
fda rare designation drug disease health grants crofelemer microvillus
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
Published: 2023-02-23 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 3.91%
H: 1.5%
C: -9.4%
fda drug patent health approved crofelemer
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
Published: 2023-01-25 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 3.23%
H: 2.93%
C: -2.94%
health approved crofelemer milestone
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator
Published: 2022-12-19 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 2.56%
H: 1.66%
C: -6.75%
health crofelemer presentation
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2022-10-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -0.35%
H: 2.85%
C: 2.56%
treatment research diarrhea breast health crofelemer cancer publication study
European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication
Published: 2022-10-17 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 13.65%
H: 7.57%
C: -1.5%
rare designation drug disease grants crofelemer
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Published: 2022-08-25 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 5.38%
H: 0.48%
C: -5.83%
health crofelemer
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review
Published: 2022-08-23 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 1.09%
H: 9.37%
C: 0.37%
fda designation drug health application crofelemer review
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
Published: 2022-06-29 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: 6.83%
H: 10.61%
C: -3.06%
treatment diarrhea health commercialization license crofelemer agreement china
UPDATED RELEASE: Jaguar Health Enters Exclusive Crofelemer Revenue Sharing Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
Published: 2022-04-01 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -4.62%
H: 0.58%
C: -6.76%
health distribution license crofelemer store
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
Published: 2022-02-16 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -0.76%
H: 1.54%
C: -3.29%
treatment fda health diarrhea crofelemer designation
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Published: 2022-02-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -0.76%
H: 0.75%
C: -8.75%
health drug approval diarrhea crofelemer
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 34M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.